306.36
Bio Rad Laboratories Inc stock is traded at $306.36, with a volume of 370.35K.
It is down -1.92% in the last 24 hours and down -12.89% over the past month.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
See More
Previous Close:
$312.36
Open:
$314.64
24h Volume:
370.35K
Relative Volume:
2.21
Market Cap:
$8.58B
Revenue:
$2.58B
Net Income/Loss:
$-778.69M
P/E Ratio:
-11.21
EPS:
-27.33
Net Cash Flow:
$223.75M
1W Performance:
-11.31%
1M Performance:
-12.89%
6M Performance:
-6.02%
1Y Performance:
-3.08%
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Name
Bio Rad Laboratories Inc
Sector
Industry
Phone
(510) 724-7000
Address
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
BIO
Bio Rad Laboratories Inc
|
306.36 | 8.58B | 2.58B | -778.69M | 223.75M | -27.33 |
![]()
ABT
Abbott Laboratories
|
131.79 | 228.58B | 41.95B | 13.40B | 6.49B | 7.65 |
![]()
BSX
Boston Scientific Corp
|
106.14 | 156.43B | 16.75B | 1.85B | 1.89B | 1.25 |
![]()
SYK
Stryker Corp
|
388.37 | 147.01B | 22.60B | 2.99B | 3.49B | 7.76 |
![]()
MDT
Medtronic Plc
|
92.20 | 118.23B | 33.00B | 4.29B | 5.50B | 3.27 |
![]()
EW
Edwards Lifesciences Corp
|
76.00 | 44.82B | 5.72B | 4.17B | 490.10M | 6.97 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-01-24 | Upgrade | Citigroup | Neutral → Buy |
Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
Jun-03-24 | Resumed | Jefferies | Hold |
Apr-03-24 | Downgrade | Citigroup | Buy → Neutral |
Dec-07-23 | Initiated | UBS | Buy |
Jun-16-23 | Initiated | Wells Fargo | Overweight |
Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
Aug-25-22 | Initiated | Credit Suisse | Outperform |
Jan-28-22 | Reiterated | Citigroup | Buy |
Jan-08-20 | Initiated | Wells Fargo | Overweight |
Jan-07-20 | Initiated | Citigroup | Buy |
Oct-17-18 | Initiated | Goldman | Buy |
Sep-20-18 | Initiated | Morgan Stanley | Equal-Weight |
Feb-16-18 | Downgrade | CL King | Buy → Neutral |
Jul-13-17 | Initiated | Wells Fargo | Outperform |
Jun-28-17 | Upgrade | Deutsche Bank | Hold → Buy |
Jan-18-17 | Initiated | Deutsche Bank | Hold |
Oct-13-16 | Initiated | CL King | Buy |
May-06-15 | Reiterated | Jefferies | Buy |
Dec-18-09 | Initiated | Maxim Group | Buy |
Nov-06-09 | Initiated | Jefferies & Co | Buy |
Jul-17-09 | Initiated | Soleil | Buy |
Sep-26-07 | Initiated | Banc of America Sec | Buy |
Feb-23-07 | Downgrade | Robert W. Baird | Outperform → Neutral |
View All
Bio Rad Laboratories Inc Stock (BIO) Latest News
Bio-Rad Laboratories, Inc. (NYSE:BIO) Stake Cut by Allspring Global Investments Holdings LLC - MarketBeat
Enzyme Linked Immunosorbent Assay Market Growth, Share, - openPR
Bio-Rad Laboratories Inc (BIO) Q4 2024 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance
Q4 EPS Forecast for Bio-Rad Laboratories Boosted by Analyst - MarketBeat
Chromatography Systems Market: In-Depth Exploration of Key - openPR
Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies - BioSpace
Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results - BioSpace
Chemiluminescence Imaging Market Booming Innovation: Witness - openPR
Bio-Rad Laboratories Reports 2024 Earnings and Strategic Plans - TipRanks
Strategic Financial Concepts LLC Invests $3.56 Million in Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
Bio-Rad Laboratories, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Bio-Rad: Q4 Earnings Snapshot - Thehour.com
Earnings call transcript: Bio-Rad Q4 2024 results miss forecasts - MSN
Bio-Rad Labs stock down 4% as Q4 revenue and guidance miss expectations - MSN
Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates - Nasdaq
Bio-Rad set to acquire Stilla Technologies By Investing.com - Investing.com Australia
Bio-Rad set to acquire Stilla Technologies - Investing.com
Bio-Rad offers to acquire digital PCR developer Stilla Technologies - MSN
Oversold Conditions For Bio-Rad Laboratories - Nasdaq
Major PCR Tech Acquisition: Bio-Rad Sets Sights on Stilla's Next-Gen Digital Platform - StockTitan
Wells Fargo & Company Cuts Bio-Rad Laboratories (NYSE:BIO) Price Target to $345.00 - MarketBeat
Immunoassay Market Size Expected to Reach USD 53,970 Million by 2034 with 5.1% CAGR | Statifacts Report - GlobeNewswire Inc.
Nuclear Pore Membrane Market Booming Innovation: Future - openPR
Van ECK Associates Corp Cuts Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
Sumitomo Mitsui Trust Group Inc. Decreases Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
Lecap Asset Management Ltd. Takes $510,000 Position in Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap DownWhat's Next? - MarketBeat
Bio-Rad Laboratories (NYSE:BIO) Shares Down 4.2%Here's What Happened - MarketBeat
Bio-Rad Laboratories Inc (BIO) Q4 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Oncocyte secures $29.1 million to advance FDA assay - MSN
Molecular Quality Control Market Deep Research Report with - openPR
Oncocyte Prices $29 Million Stock Offerings -February 10, 2025 at 12:41 pm EST - Marketscreener.com
Oncocyte Secures $29.1Mln Funding Led By Bio-Rad To Advance Transplant Diagnostics, Stock Down - Nasdaq
Bio-Rad Laboratories (BIO) Projected to Post Earnings on Thursday - MarketBeat
Antinuclear antibody test market Size, Share, Industry - openPR
Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline - MSN
Cell Processing Instrument Market Competitive Dynamics: - openPR
KBC Group NV Sells 814 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
DAVENPORT & Co LLC Acquires 27,780 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
Biopharmaceutical Bioseparation Systems Global Report 2025: Market to Benefit from Rising Demand for Monoclonal Antibodies, Forecast to Hit $32.6 Billion by 2030 - Yahoo Finance
Robeco Institutional Asset Management B.V. Has $2.55 Million Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
Bio-Rad Launches Dye Label Kits for Antibody Conjugation - Contract Pharma
Lab-on-Chip Application Market Statistics, Competitive - openPR
Blood Market to Grow by USD 2.60 Billion (2024-2028) with Rising Number of Hospitals & Blood Banks Boosting the Market, Report on How AI is Redefining Market LandscapeTechnavio - Yahoo Finance
Bio-Rad Laboratories (BIO) to Release Quarterly Earnings on Thursday - Defense World
Bio-Rad Laboratories, Inc. (NYSE:BIO) Sees Significant Increase in Short Interest - MarketBeat
Clinical Microbiology Market Generated Opportunities, Future - openPR
Janney Montgomery Scott LLC Sells 130 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) - Defense World
Has BioRad Laboratories (BIO) Outpaced Other Medical Stocks This Year? - MSN
Bio Rad Laboratories Inc Stock (BIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):